Literature DB >> 17195762

Race and mental health diagnosis are risk factors for highly active antiretroviral therapy failure in a military cohort despite equal access to care.

Joshua D Hartzell1, Katherine Spooner, Robin Howard, Scott Wegner, Glenn Wortmann.   

Abstract

BACKGROUND: Data suggest that African Americans have lower rates of virologic suppression using highly active antiretroviral therapy (HAART), possibly because of socioeconomic status and access to care. In a US Military clinic, where beneficiaries have ready access to no-cost health care, the impact of several variables (including race) on HIV virologic suppression were examined.
METHODS: Retrospective analysis of antiretroviral-naive patients who began HAART between 1997 and 2003. Demographics, viral loads, CD4 cell counts, and mental health diagnoses were analyzed.
RESULTS: The charts of 129 individuals who initiated their first antiretroviral regimen during the period of observation were evaluated. The overall efficacy of reaching viral suppression was 71% at 12 months and 56% at 24 months. HIV suppression was achieved at 12 months by 63% of African Americans and 92% of whites (P = 0.001). Mental health diagnosis was associated with failure at 24 months (38 vs. 61%; P = 0.034). Being white (odds ratio = 3.5, 95% confidence interval [CI]: 1.2 to 10.3; P = 0.022) and lacking a mental health diagnosis (odds ratio = 8.7, 95% CI: 2.4 to 32.1; P = 0.001) were both associated with increased efficacy at 24 months by multivariate analysis.
CONCLUSIONS: African-American race and the presence of a mental health diagnoses were independently associated with antiretroviral failure. Equal access to care yields high efficacy rates with HAART but does not fully equilibrate racial differences in virologic failure.

Entities:  

Mesh:

Year:  2007        PMID: 17195762     DOI: 10.1097/QAI.0b013e31802f83a6

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  32 in total

1.  Disparities in outcomes for African American and Latino subjects in the Flexible Initial Retrovirus Suppressive Therapies (FIRST) trial.

Authors:  Thomas P Giordano; Glenn Bartsch; Yafeng Zhang; Ellen Tedaldi; Judith Absalon; Sharon Mannheimer; Avis Thomas; Rodger D MacArthur
Journal:  AIDS Patient Care STDS       Date:  2010-05       Impact factor: 5.078

2.  Racial/Ethnic disparities in ART adherence in the United States: findings from the MACH14 study.

Authors:  Jane M Simoni; David Huh; Ira B Wilson; Jie Shen; Kathy Goggin; Nancy R Reynolds; Robert H Remien; Marc I Rosen; David R Bangsberg; Honghu Liu
Journal:  J Acquir Immune Defic Syndr       Date:  2012-08-15       Impact factor: 3.731

3.  A closer look at depression and its relationship to HIV antiretroviral adherence.

Authors:  Glenn J Wagner; Kathy Goggin; Robert H Remien; Marc I Rosen; Jane Simoni; David R Bangsberg; Honghu Liu
Journal:  Ann Behav Med       Date:  2011-12

4.  Benefits of family and social relationships for Thai parents living with HIV.

Authors:  Mary Jane Rotheram-Borus; Judith A Stein; Chuleeporn Jiraphongsa; Siwaporn Khumtong; Sung-Jae Lee; Li Li
Journal:  Prev Sci       Date:  2010-09

5.  A randomized controlled trial of an HIV/AIDS Symptom Management Manual for depressive symptoms.

Authors:  Lucille S Eller; Kenn M Kirksey; Patrice K Nicholas; Inge B Corless; William L Holzemer; Dean J Wantland; Suzanne S Willard; Linda Robinson; Mary Jane Hamilton; Elizabeth F Sefcik; Shahnaz Moezzi; Marta Rivero Mendez; Maria Rosa; Sarie Human
Journal:  AIDS Care       Date:  2012-08-13

6.  Do Symptoms of Depression Interact with Substance Use to Affect HIV Continuum of Care Outcomes?

Authors:  Anthony T Fojo; Catherine R Lesko; Keri L Calkins; Richard D Moore; Mary E McCaul; Heidi E Hutton; William C Mathews; Heidi Crane; Katerina Christopoulos; Karen Cropsey; Michael J Mugavero; Kenneth Mayer; Brian W Pence; Bryan Lau; Geetanjali Chander
Journal:  AIDS Behav       Date:  2019-03

7.  Antiretroviral use among active injection-drug users: the role of patient-provider engagement and structural factors.

Authors:  Amy R Knowlton; Julia H Arnsten; Lois J Eldred; James D Wilkinson; Starley B Shade; Amy S Bohnert; Cui Yang; Lawrence S Wissow; David W Purcell
Journal:  AIDS Patient Care STDS       Date:  2010-07       Impact factor: 5.078

8.  Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysis.

Authors:  Heather J Ribaudo; Kimberly Y Smith; Gregory K Robbins; Charles Flexner; Richard Haubrich; Yun Chen; Margaret A Fischl; Bruce R Schackman; Sharon A Riddler; Roy M Gulick
Journal:  Clin Infect Dis       Date:  2013-09-17       Impact factor: 9.079

9.  Depressive symptoms, self-esteem, HIV symptom management self-efficacy and self-compassion in people living with HIV.

Authors:  L S Eller; M Rivero-Mendez; J Voss; W-T Chen; P Chaiphibalsarisdi; S Iipinge; M O Johnson; C J Portillo; I B Corless; K Sullivan; L Tyer-Viola; J Kemppainen; C Dawson Rose; E Sefcik; K Nokes; J C Phillips; K Kirksey; P K Nicholas; D Wantland; W L Holzemer; A R Webel; J M Brion
Journal:  AIDS Care       Date:  2013-10-04

10.  Race/ethnicity and risk of AIDS and death among HIV-infected patients with access to care.

Authors:  Michael J Silverberg; Wendy Leyden; Charles P Quesenberry; Michael A Horberg
Journal:  J Gen Intern Med       Date:  2009-07-16       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.